The fact that both linagliptin and glimepiride decreased obesity/T2D-induced c-Fos expression in GLP-1-producing neurons may indicate that this effect occurs via glycemia regulation, since these drugs normalize glycemia through unrelated mechanisms. Here, GLP1R is linked to type 2 diabetes mellitus.